Drugs / 2D UC-MSCs
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT07299123 Comparator | Aug 2022 → Dec 2026 expected | aplastic anemia, bone marrow failure syndrome | Chinese PLA General Hospital | Enrolling by invitation | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 2D UC-MSCs | “5 × 10⁵/kg 2D UC-MSCs at 4 h before HSC infusion” NCT07299123 ↗ |
| Known as | conventional 2D-cultured UC-MSCs | “The control group was transfused with conventional 2D-cultured UC-MSCs” NCT07299123 ↗ |
| Modality | Cell therapy | “Umbilical Cord Mesenchymal Stem Cells” NCT07299123 ↗ |